Compare LFVN & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LFVN | GRML |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.5M | 51.5M |
| IPO Year | 1996 | 2022 |
| Metric | LFVN | GRML |
|---|---|---|
| Price | $5.17 | $0.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | 227.7K | ★ 2.9M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | ★ 226.09 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $203,204,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.23 | ★ N/A |
| Revenue Growth | ★ 1.86 | N/A |
| 52 Week Low | $3.90 | $0.27 |
| 52 Week High | $15.00 | $0.55 |
| Indicator | LFVN | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 51.44 | 38.33 |
| Support Level | $4.21 | $0.31 |
| Resistance Level | $5.37 | $0.43 |
| Average True Range (ATR) | 0.40 | 0.05 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 36.05 | 7.82 |
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.